CurrentHighmark Blueshield NenyPolicy N/A

Outpatient Leqvio (inclisiran) Injectable Request Form — Coverage Criteria

Form and requirements to request outpatient medical benefit coverage for Leqvio (inclisiran) for Highmark members; used by ordering providers and facilities to document clinical indications and prior therapies. Affects providers submitting Leqvio requests for Highmark Blueshield NENY members.

Policy Summary

PayerHighmark Blueshield Neny

PolicyOutpatient Leqvio (inclisiran) Injectable Request Form — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionSubmit the completed Outpatient Medical Injectable Leqvio Request Form by fax to 833-581-1861 with patient, provider, drug, diagnosis, and supporting clinical documentation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1drug addressed

3indication sections

≥2required statin trials

Faxsubmission method

Coverage Criteria for Leqvio (inclisiran)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial therapy / general authorization criteria

Covered when ALL of the following are met (form collects these elements to support coverage determination):

General requirements: Leqvio prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist; used as adjunct to maximally tolerated statin therapy unless the member is statin intolerant; documentation of prior PCSK9 inhibitor failure if applicable (≥3 months).

Elements appear on form for all indications

Statin tolerance/attempts: While receiving at least two (2) separate trials of different statins, member experienced statin-related rhabdomyolysis resolved on discontinuation, skeletal-related muscle symptoms resolved on discontinuation, LFTs increase to 3x ULN, CK increase to 10x ULN, or hospitalization for severe statin adverse event; OR documentation that member is on maximally tolerated statin therapy with intolerance documented.2 separate statin trials referenced

Form queries multiple statin intolerance criteria

ASCVD-specific criteria

For Clinical Atherosclerotic Cardiovascular Disease (ASCVD):

ASCVD manifestations: Presence of at least one ASCVD condition: acute coronary syndrome; history of transient ischemic attack; coronary or other arterial revascularization; peripheral arterial disease presumed to be of atherosclerotic origin; history of myocardial infarction; stable or unstable angina; history of stroke.

Form lists each ASCVD item as yes/no

HeFH-specific criteria

For Heterozygous Familial Hypercholesterolemia (HeFH):

HeFH diagnostic criteria: Clinical documentation of HeFH defined by ONE of: genetic confirmation of pathogenic variant at LDLR, APOB, PCSK9, or LDLRAP1; tendon xanthomas; corneal arcus before age 45; tuberous xanthomas; xanthelasma; WHO/Dutch Lipid Clinical Network criteria (score >8); Simon Broome definite criteria; MEDPED definite diagnosis; or documentation of untreated LDL-C ≥190 mg/dL (or ≥160 mg/dL if <20 years).

Form lists each diagnostic option as yes/no

Primary hyperlipidemia criteria

For Primary Hyperlipidemia (not ASCVD/HeFH/HoFH):

Primary hyperlipidemia criteria: Serum LDL-C greater than or equal to 70 mg/dL AND fasting triglycerides less than 400 mg/dL.LDL-C >=70 mg/dL; TG <400 mg/dL

Form requests these lab thresholds

Continuation/response

Response and continuation criteria:

Response documentation: For new starts or continuation, documentation of LDL-C reduction from baseline or other positive clinical response (e.g., LDL-C reduction) is requested on the form to demonstrate benefit.

Used to assess ongoing benefit

This request form does not include pathways for Homozygous Familial Hypercholesterolemia (HoFH). The form and the coverage criteria focus on Clinical Atherosclerotic Cardiovascular Disease (ASCVD), Heterozygous Familial Hypercholesterolemia (HeFH), and Primary Hyperlipidemia only, and providers should not use this form to document HoFH-specific diagnostic or treatment requirements.

Requests lacking required clinical documentation may be considered not medically necessary. Common missing elements include the indication-specific evidence requested on the form (for example, ASCVD manifestations, HeFH diagnostic criteria, or primary hyperlipidemia lab thresholds), absence of documentation that Leqvio will be used as an adjunct to maximally tolerated statin therapy (unless statin intolerance is documented), missing documentation of prior PCSK9 inhibitor failure when applicable, and absent baseline or follow-up LDL-C response data. The form explicitly queries prior statin trials and statin‑intolerance events (including at least two separate statin trials), specific lab abnormalities, and whether there has been documentation of LDL‑C reduction from baseline.

Provider Actions, Submission, and Requirements

Prior Authorization

How to submit the form and prior authorization

Submit the completed Leqvio (inclisiran) outpatient medical injectable request form and all supporting clinical documentation to the Medical Benefit prior authorization team. Fax the completed form to 833-581-1861. Ensure the form is fully completed to avoid delays.

Fax: 833-581-1861
Include member eligibility verification prior to submission

Step Therapy

Statin trials and PCSK9 step requirements

Document that the member has been prescribed Leqvio as an adjunct to maximally tolerated statin therapy unless statin intolerant. If a PCSK9 inhibitor step is required, include documentation of failure of an FDA‑approved PCSK9 inhibitor (e.g., alirocumab or evolocumab) for at least three (3) months when applicable.

Must indicate use as adjunct to maximally tolerated statin therapy or state specific statin intolerance reason(s)
If applicable, document ≥3 months trial and failure of PCSK9 inhibitor (alirocumab or evolocumab)

Documentation Required

Required documentation to submit

Attach complete clinical documentation with the request form. Required fields on the form include: member demographics (member name, date of birth, member ID), ordering/attending provider name and NPI, provider contact phone/fax, servicing facility/vendor name and NPI, requested start date of service, ICD‑10 diagnosis code(s) and description, drug name (LEQVIO), strength/dose, date of service, directions, quantity (# doses/visits), and indication details. For clinical justification include: whether prescribed by or in consultation with a cardiologist/endocrinologist/lipid specialist, documentation of maximally tolerated statin therapy or statin intolerance details, results of prior statin trials (including LFTs, CK, hospitalizations), baseline and follow-up LDL‑C values showing response, and copies of any prior PCSK9 inhibitor therapy records.

Member demographics: name, DOB, member ID
Provider: ordering/attending name, NPI, address, phone, fax
Facility: servicing facility/vendor name and NPI
Drug: LEQVIO, strength/dose, directions, quantity, date of service
Diagnosis: ICD‑10 code(s) and description
Clinical: consultation specialty (cardiology/endocrinology/lipid specialist), documentation of maximally tolerated statin therapy or detailed statin intolerance, results of LFTs and CK if relevant, hospitalization records for severe statin adverse events, baseline and post‑treatment LDL‑C values
Attach all pertinent clinical records and lab results

Denial Risk

Potential denial triggers

Incomplete or missing clinical information is a common reason for denial. Potential triggers include absence of documentation of maximally tolerated statin therapy or specification of statin intolerance, failure to provide prior PCSK9 inhibitor trial details when required, missing ICD‑10 diagnosis codes, lack of baseline or follow‑up LDL‑C values, or an incomplete request form (missing provider or member identifiers). Ensure all required form fields and attachments are included to reduce denial risk.

Missing documentation of maximally tolerated statin therapy or specific statin intolerance criteria
No documentation of ≥3 months PCSK9 inhibitor trial when step required
Absent or incorrect ICD‑10 diagnosis codes
No baseline or follow‑up LDL‑C values demonstrating response
Incomplete form (missing member or provider identifiers, drug dose/directions, or requested start date)

OpenPayer

Outpatient Leqvio (inclisiran) Injectable Request Form — Coverage Criteria

Coverage Criteria for Leqvio (inclisiran)

Coding and Clinical Thresholds

Provider Actions, Submission, and Requirements

Background

Definitions